Omeros price target lowered to $16 from $19 at Burrill Burrill lowered its price target for Omeros after the company announced that OMS103HP did not meet its primary endpoint in patients undergoing arthroscopic partial meniscectomy surgery. The firm notes that OMS103HP achieved statistically significant reduction of postoperative pain, though, and keeps an Outperform rating on the stock.
Omeros receives positive opinion from EMA's committee for Omidria Omeros announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for Omidria 1%/0.3%. Omidria is used during cataract surgery and other intraocular lens replacement procedures to maintain mydriasis, prevent miosis, and reduce postoperative eye pain. Cataract surgery and IOL replacement are among the most common surgical procedures worldwide, with approximately 3.9 million of them expected to be performed in Western Europe alone in 2015. Omidria was approved by the FDA in 2014 and last month was made broadly available nationwide for commercial use.